Exhibit 99-1
The Common Stock of BioPharmX Corp. reported in Table 1 and the Warrants
reported in Table II of the attached Form 4 are beneficially owned by Franklin
Biotechnology Discovery Fund, a series of Franklin Strategic Series, an
investment company registered under the Investment Company Act of 1940, that has
  an interest in 1,816,000 shares of such Common Stock and 108,000 of such
Warrants, and Franklin Templeton Investment Funds- Franklin Biotechnology
Discovery Fund, a SICAV incorporated in Luxembourg, that has an interest in
2,824,000 shares of such Common Stock and 162,000 of such Warrants.  Each of
these funds (collectively, the "Clients") is an investment advisory client of
Franklin Advisers, Inc. (FAV), a wholly-owned subsidiary of Franklin Resources,
Inc. (FRI).  FAV may be deemed to beneficially own the Common Stock for purposes
  of Rule 13d-3, and accordingly for purposes of section 16(a), under the
Securities Exchange Act of 1934, as amended (the Act), in its capacity as the
investment adviser to the Clients pursuant to investment management contracts
that grant investment and/or voting power to FAV.  When an investment management
  contract (including a sub-advisory agreement) delegates to FAV investment
discretion or voting power over the securities held in the investment advisory
accounts that are subject to that agreement, FRI treats FAV as having sole
investment discretion or voting authority, as the case may be, unless the
agreement specifies otherwise.
Beneficial ownership by FRI, FAV and their affiliates is reported in conformity
with the guidelines articulated by the SEC staff in Release No. 34-39538
(January 12, 1998) relating to organizations, such as FRI, where related
entities exercise voting and investment powers over the securities being
reported independently from each other.  The voting and investment powers held
by Franklin Mutual Advisers, LLC (FMA), an indirect wholly owned investment
management subsidiary of FRI, are exercised independently from FRI and from all
other investment management subsidiaries of FRI (FRI, its affiliates and the
investment management subsidiaries other than FMA are, collectively, FRI
affiliates). Furthermore, internal policies and procedures of FMA and FRI
establish informational barriers that prevent the flow between FMA and the FRI
affiliates of information that relates to the voting and investment powers over
the securities owned by their respective investment management clients.
Consequently, FMA and the FRI affiliates report the securities over which they
hold investment and voting power separately from each other for purposes of
Sections 13 and 16 of the Act.
Charles B. Johnson and Rupert H. Johnson, Jr. (the Principal Shareholders) each
own in excess of 10% of the outstanding common stock of FRI and are the
principal stockholders of FRI.  FRI and the Principal Shareholders may be deemed
   to be, for purposes of Rule 13d-3 under the Act, the beneficial owners of
securities held by persons and entities for whom or for which FRI's subsidiaries
  provide investment management services.  FRI, the Principal Shareholders and
FAV disclaim any pecuniary interest in any of the Common Stock.  In addition,
the filing of this Form 4 on behalf of the Principal Shareholders, FRI and FAV
should not be construed as an admission that any of them is, and each disclaims
that it is, the beneficial owner, as defined in Rule 13d-3, of any of the Common
  Stock.
FRI, the Principal Shareholders, and FAV believe that they are not a group
within the meaning of Rule 13d-5 under the Act and that they are not otherwise
required to attribute to each other the beneficial ownership of the Common Stock
  held by any of them or by any persons or entities for whom or for which FAV
provides investment management services.